^
    Back
    Association details:
    Biomarker:NRAS wild-type
    Cancer:Rectal Cancer
    Drug:Vectibix (panitumumab) (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Rectal cancer: Systemic therapy for advanced or metastatic disease...FOLFOX + panitumumab (KRAS/NRAS/BRAF WT only)...FOLFIRI + panitumumab (KRAS/NRAS/BRAF WT only)...FOLFIRINOX or mFOLFIRINOX + panitumumab...Irinotecan + panitumumab (KRAS/NRAS/BRAF WT only)
    Secondary therapy:
    FOLFIRI; FOLFOX; irinotecan; FOLFIRINOX